Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced it would demonstrate Genedata Screener® 7.0 at the Drug Discovery & Development Week Conference. Screener 7.0 is the newest version of the award-winning enterprise system for high throughput screening (HTS) and high content screening (HCS) analyses, which streamlines data analyses and accelerates lead discovery. Drug Discovery & Development Week Conference is a comprehensive display of drug discovery technology including technologies applicable to all phases of drug discovery to clinic. Genedata will conduct Screener sessions on August 4 and August 5 at the World Trade Center Exhibit Hall (Booth #335).
“Screener enables scientists and researchers to modernize their data management infrastructure and is fast becoming the lead discovery software platform of choice for forward-thinking pharmaceutical and biotechnology companies,” said Dr. Othmar Pfannes, CEO of Genedata. “While this is due in large part to the system’s inherent scalability and ease-of-use,” continued Pfannes, “Screener 7.0 sets new standards of excellence for statistically sound processing of extremely large and complex data sets and can easily integrate with multiple technologies.”
Fully compatible with widely-used systems such as Thermo Scientific Cellomics Store image management system, Screener integrates with any plate-based HCS instrument, image analysis software or image database via its HCS Image API. With sophisticated algorithms and dedicated visualizations, Screener ensures that HCS yields high-quality data and comprehensive results, including their use by global reporting, data mining and decision support functions. Screener’s five application modules and database process, manage and analyze massive volumes of HTS and HCS data.
Best Practices Award
“In an era of increased M&A activity and market consolidation, Screener gives pharmaceutical and life science research companies a robust, stable, and advanced platform that aligns business processes and provides a springboard for future growth,” noted Pfannes. Screener is the platform upon which Genedata and Amgen developed the Amgen Lead Discovery Informatics (ALDI) system, awarded a Bio-IT World 2009 Best Practices Award for Drug Discovery. Established in 2003, Bio-IT World’s Best Practices Awards Program recognizes organizations for their outstanding innovations and excellence in the use of technologies, practices, and novel business strategies that will advance drug discovery, development, biomedical research, and clinical trials.
In the ALDI project, Screener helped align 5 research sites previously using different research tools and processes, and enabled research teams to increase productivity rates by up to 80%, slash false-positives and false-negatives by more than 50%, and accelerate assay set ups – now typically in under 30 minutes per assay. Pfannes underscored, “These data validate the system’s ability to effectively streamline screening analysis workflows, standardize data processing procedures, and accelerate lead discovery enterprise-wide.”
Editorial Note: To schedule a briefing with Genedata or Screener demo at the Drug Discovery & Development Week Conference, email: email@example.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.